A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
University Hospital Tübingen: Advancing MRI Efficiency in Glioblastoma Care with Deep Learning
This study explores the use of deep learning (DL) to optimize MRI protocols for glioblastoma patients. Glioblastomas, known for being the most…
Heidelberg University Hospital: Key Imaging Features to Distinguish Solid Pseudopapillary Neoplasms from Pancreatic Neuroendocrine Neoplasms
Solid pseudopapillary neoplasms (SPNs), or Frantz tumors, are rare pancreatic tumors accounting for 2-3% of all pancreatic neoplasms. These tumors…
Multicentric Study: Comparison of Diagnostic Guidelines for Hepatocellular Carcinoma
Recent advancements in MRI techniques and tumor biology have led to updated hepatocellular carcinoma (HCC) diagnostic guidelines from various liver…